静脉泊沙康唑在高危侵袭性真菌病患者中的药代动力学与安全性:3期随机开放标签研究
该研究纳入237例中性粒细胞减少的AML/MDS患者或异基因HSCT后侵袭性真菌病高危受者,先接受静脉泊沙康唑300 mg每日两次(第1天)后每日一次4-28天,随后随机转为口服悬液完成28天疗程。稳态Cavg为1500 ng/mL,Cmin为1090 ng/mL,侵袭性真菌病发生率1%,常见治疗相关不良事件为腹泻8%、恶心5%、皮疹5%。
要点
- 静脉泊沙康唑300 mg方案耐受良好,稳态暴露充分。
- 稳态Cavg在HSCT受者与AML/MDS患者中相似。
- 高危人群中侵袭性真菌病发生率低(1%)。
核心结论
- 静脉泊沙康唑300 mg耐受良好,达到充分的稳态系统暴露,且在该高危人群中侵袭性真菌病发生率低。
研究设计与样本
- 两部分(1B/3期)、序贯、开放标签、多中心研究,纳入237例中性粒细胞减少的AML或MDS患者或异基因HSCT后侵袭性真菌病高危受者。
- 患者第1天接受静脉泊沙康唑300 mg每日两次,随后300 mg每日一次4-28天;至少5天后随机转为口服悬液400 mg每日两次或200 mg每日三次完成28天疗程。
主要发现
- 平均泊沙康唑Cmin为1320 ng/mL(第6天)和1297 ng/mL(第8天);稳态Cmin为1090 ng/mL(第10天)。
- 平均稳态泊沙康唑Cavg为1500 ng/mL(第10天或14天),HSCT受者为1560 ng/mL,AML/MDS患者为1470 ng/mL。
- 最常见的治疗相关不良事件为腹泻(8%)、恶心(5%)和皮疹(5%)。
- 237例患者中报告侵袭性真菌病3例(1%;2例确诊,1例 probable)。
临床怎么用
- 对于中性粒细胞减少的AML/MDS患者或异基因HSCT后侵袭性真菌病高危受者,可考虑静脉泊沙康唑300 mg方案进行预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A two-part (Phase 1B/3), sequential, open-label, multicentre study evaluated the pharmacokinetics (PK) and safety of intravenous (iv) posaconazole given as antifungal prophylaxis to neutropenic patients with AML or myelodysplastic syndrome (MDS) or to recipients at risk of invasive fungal disease (IFD) after allogeneic HSCT. METHODS: Patients (N = 237) received 300 mg of posaconazole iv twice daily on day 1, followed by 300 mg of posaconazole iv once daily for 4-28 days. After at least 5 days, patients were randomly assigned to receive posaconazole oral suspension, 400 mg twice daily or 200 mg three times daily, to complete a 28 day treatment course. Primary PK parameters were steady-state average concentration over the dosing interval (Cavg) and posaconazole trough levels (Cmin). RESULTS: Mean posaconazole Cmin was 1320 ng/mL (day 6) and 1297 ng/mL (day 8); steady-state Cmin was 1090 ng/mL (day 10). Mean steady-state posaconazole Cavg was 1500 ng/mL (day 10 or 14) and was similar in HSCT recipients (1560 ng/mL) and AML/MDS patients (1470 ng/mL). The most commonly reported treatment-related adverse events were diarrhoea (8%), nausea (5%) and rash (5%). IFD was reported in 3/237 patients (1%; 2 proven, 1 probable). CONCLUSIONS: Intravenous posaconazole at 300 mg was well tolerated, resulted in adequate steady-state systemic exposure and was associated with a low incidence of IFD in this population at high risk. TRIAL REGISTRY AND NUMBER: ClinicalTrials.gov, NCT01075984.
引用
- Cornely OA, Robertson MN, Haider S, et al. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017. PMID: 28961714. doi:10.1093/jac/dkx263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。